IL315025A - Compounds and preparations for the treatment of hematological disorders - Google Patents
Compounds and preparations for the treatment of hematological disordersInfo
- Publication number
- IL315025A IL315025A IL315025A IL31502524A IL315025A IL 315025 A IL315025 A IL 315025A IL 315025 A IL315025 A IL 315025A IL 31502524 A IL31502524 A IL 31502524A IL 315025 A IL315025 A IL 315025A
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- compounds
- hematological disorders
- treating hematological
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579502P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/058194 WO2019089580A1 (en) | 2017-10-31 | 2018-10-30 | Compounds and compositions for treating hematological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315025A true IL315025A (en) | 2024-10-01 |
Family
ID=66328095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315025A IL315025A (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL274248A IL274248B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL308364A IL308364B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274248A IL274248B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL308364A IL308364B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10758518B2 (enExample) |
| EP (2) | EP4410377A3 (enExample) |
| JP (3) | JP7241747B2 (enExample) |
| KR (2) | KR20240130818A (enExample) |
| CN (2) | CN117064897A (enExample) |
| AU (3) | AU2018359248B2 (enExample) |
| BR (1) | BR112020008214A2 (enExample) |
| CA (1) | CA3079628A1 (enExample) |
| DK (1) | DK3704108T3 (enExample) |
| EA (1) | EA202090497A1 (enExample) |
| ES (1) | ES2979273T3 (enExample) |
| FI (1) | FI3704108T3 (enExample) |
| HR (1) | HRP20240700T1 (enExample) |
| HU (1) | HUE067356T2 (enExample) |
| IL (3) | IL315025A (enExample) |
| LT (1) | LT3704108T (enExample) |
| MX (2) | MX2020003666A (enExample) |
| MY (1) | MY203827A (enExample) |
| PH (1) | PH12020550457A1 (enExample) |
| PL (1) | PL3704108T3 (enExample) |
| PT (1) | PT3704108T (enExample) |
| RS (1) | RS65572B1 (enExample) |
| SG (1) | SG11202002386WA (enExample) |
| SI (1) | SI3704108T1 (enExample) |
| SM (1) | SMT202400216T1 (enExample) |
| WO (1) | WO2019089580A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE041926T2 (hu) | 2014-01-13 | 2019-06-28 | Aurigene Discovery Tech Ltd | IRAK4 inhibitor biciklusos heterociklilszármazékok |
| HUE062648T2 (hu) | 2017-03-31 | 2023-11-28 | Aurigene Oncology Ltd | Vegyületek és készítmények hematológiai rendellenességek kezelésére |
| MY203827A (en) * | 2017-10-31 | 2024-07-19 | Curis Inc | Compounds and compositions for treating hematological disorders |
| PT4015513T (pt) * | 2019-09-24 | 2023-12-19 | Shanghai Meiyue Biotech Dev Co Ltd | Inibidor de irak e seu método de preparação e sua utilização |
| CN115698021A (zh) | 2020-04-07 | 2023-02-03 | 拜耳公司 | 经取代的噻唑并吡啶、其盐及其作为除草活性物质的用途 |
| CA3188171A1 (en) * | 2020-08-03 | 2022-02-10 | Reinhard Von Roemeling | Compositions and methods for treating diseases and disorders |
| US20230414582A1 (en) * | 2020-11-18 | 2023-12-28 | Curis, Inc. | Methods of treating diseases and disorders |
| EP4269409A4 (en) * | 2020-12-25 | 2024-12-11 | Medshine Discovery Inc. | AMIDE-OXAZOLE COMPOUND |
| MX2023011790A (es) * | 2021-04-08 | 2023-10-11 | Curis Inc | Terapias combinadas para tratar el cancer. |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| TWI890016B (zh) | 2021-12-23 | 2025-07-11 | 大陸商杭州多域生物技術有限公司 | 一種五員并六員化合物、製備方法、藥物組成物和應用 |
| WO2025090844A1 (en) * | 2023-10-27 | 2025-05-01 | Curis, Inc. | Methods of treating cancer associated with reduced interleukin 1 beta expression |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| ATE151633T1 (de) | 1990-05-18 | 1997-05-15 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden- cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| ATE250923T1 (de) | 1997-07-29 | 2003-10-15 | Alcon Lab Inc | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| EP1051167A1 (en) | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-) -bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2004099156A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| JP5279987B2 (ja) | 2003-05-20 | 2013-09-04 | 味の素株式会社 | アミド誘導体 |
| JP2006526660A (ja) | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｒ１レセプターのモジュレーター |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| CA2541299A1 (en) | 2003-10-07 | 2005-04-14 | Renovis, Inc. | Amide compounds as ion channel ligands and uses thereof |
| US20090005249A1 (en) | 2004-04-22 | 2009-01-01 | Bayer Cropscience Lp | Method and composition for controlling weeds |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| ATE404555T1 (de) | 2004-12-17 | 2008-08-15 | Lilly Co Eli | Neue mch-rezeptorantagonisten |
| EP1828207B1 (en) | 2004-12-17 | 2009-10-28 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| WO2007095124A2 (en) | 2006-02-10 | 2007-08-23 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| MX2008012482A (es) | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| BRPI0716549A2 (pt) | 2006-09-07 | 2013-09-24 | Biogen Idec Inc | moduladores de quinase associada de interleucina-1 |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| JP5399262B2 (ja) | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒおよびｆｘｒのモジュレーター |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| US8110572B2 (en) | 2007-07-16 | 2012-02-07 | Abbott Laboratories | Inhibitors of protein kinases |
| AU2008285722B2 (en) | 2007-08-08 | 2013-06-20 | Merck Serono S.A. | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
| EP2252617A1 (en) | 2008-02-13 | 2010-11-24 | CGI Pharmaceuticals, Inc. | 6-aryl-imidaz0[l, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| WO2010059602A2 (en) | 2008-11-19 | 2010-05-27 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
| US8283360B2 (en) | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| EP2393781B1 (en) | 2008-12-23 | 2014-03-12 | F. Hoffmann-La Roche AG | Dihydropyridone ureas as p2x7 modulators |
| KR101804588B1 (ko) | 2009-10-13 | 2017-12-04 | 리간드 파마슈티칼스 인코포레이티드 | 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도 |
| US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| CA2793697A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (pdk1) |
| PT2585064T (pt) | 2010-06-24 | 2017-08-08 | Chemocentryx Inc | Antagonistas do c5ar |
| WO2012007375A1 (en) | 2010-07-13 | 2012-01-19 | F. Hoffmann-La Roche Ag | Pyrazolo [1, 5a] pyrimidine and thieno [3, 2b] pyrimidine derivatives as irak4 modulators |
| PL2730564T3 (pl) | 2010-11-19 | 2018-09-28 | Ligand Pharmaceuticals Inc. | Heterocykliczne aminy i ich zastosowania |
| SI2655357T1 (sl) | 2010-12-20 | 2016-10-28 | Merck Serono S.A. | Derivati indazolil triazola kot zaviralci IRAK |
| CN103608017B (zh) | 2011-04-12 | 2017-02-15 | 美国卫生和人力服务部 | 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂 |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| JP6372666B2 (ja) | 2012-11-03 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | サイトメガロウイルスの阻害剤 |
| EP2999470B1 (en) | 2013-05-22 | 2017-08-16 | Children's Hospital Medical Center | Combination therapy for mds |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CA2935880A1 (en) | 2014-01-10 | 2015-07-16 | Aurigene Discovery Technologies Limited | Indazole compounds as irak4 inhibitors |
| HUE041926T2 (hu) | 2014-01-13 | 2019-06-28 | Aurigene Discovery Tech Ltd | IRAK4 inhibitor biciklusos heterociklilszármazékok |
| WO2015119998A1 (en) | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| SG11201610009XA (en) * | 2014-06-20 | 2017-01-27 | Aurigene Discovery Tech Ltd | Substituted indazole compounds as irak4 inhibitors |
| MX2018000396A (es) | 2015-07-15 | 2018-05-02 | Aurigene Discovery Tech Ltd | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). |
| AU2016293441A1 (en) | 2015-07-15 | 2018-02-01 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as IRAK-4 inhibitors |
| DK3331879T3 (da) * | 2015-08-04 | 2020-08-10 | Rigel Pharmaceuticals Inc | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne |
| CA3038130A1 (en) | 2016-10-28 | 2018-05-03 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| MY203827A (en) * | 2017-10-31 | 2024-07-19 | Curis Inc | Compounds and compositions for treating hematological disorders |
-
2018
- 2018-10-30 MY MYPI2020001530A patent/MY203827A/en unknown
- 2018-10-30 BR BR112020008214-7A patent/BR112020008214A2/pt not_active Application Discontinuation
- 2018-10-30 PL PL18873778.7T patent/PL3704108T3/pl unknown
- 2018-10-30 EA EA202090497A patent/EA202090497A1/ru unknown
- 2018-10-30 RS RS20240586A patent/RS65572B1/sr unknown
- 2018-10-30 ES ES18873778T patent/ES2979273T3/es active Active
- 2018-10-30 JP JP2020523028A patent/JP7241747B2/ja active Active
- 2018-10-30 WO PCT/US2018/058194 patent/WO2019089580A1/en not_active Ceased
- 2018-10-30 KR KR1020247027492A patent/KR20240130818A/ko active Pending
- 2018-10-30 IL IL315025A patent/IL315025A/en unknown
- 2018-10-30 SG SG11202002386WA patent/SG11202002386WA/en unknown
- 2018-10-30 CN CN202311020285.0A patent/CN117064897A/zh active Pending
- 2018-10-30 HR HRP20240700TT patent/HRP20240700T1/hr unknown
- 2018-10-30 LT LTEPPCT/US2018/058194T patent/LT3704108T/lt unknown
- 2018-10-30 IL IL274248A patent/IL274248B2/en unknown
- 2018-10-30 DK DK18873778.7T patent/DK3704108T3/da active
- 2018-10-30 SI SI201831106T patent/SI3704108T1/sl unknown
- 2018-10-30 AU AU2018359248A patent/AU2018359248B2/en active Active
- 2018-10-30 EP EP24168755.7A patent/EP4410377A3/en active Pending
- 2018-10-30 FI FIEP18873778.7T patent/FI3704108T3/fi active
- 2018-10-30 SM SM20240216T patent/SMT202400216T1/it unknown
- 2018-10-30 IL IL308364A patent/IL308364B2/en unknown
- 2018-10-30 KR KR1020207013352A patent/KR102697663B1/ko active Active
- 2018-10-30 PT PT188737787T patent/PT3704108T/pt unknown
- 2018-10-30 CN CN201880066904.0A patent/CN111225911B/zh active Active
- 2018-10-30 MX MX2020003666A patent/MX2020003666A/es unknown
- 2018-10-30 CA CA3079628A patent/CA3079628A1/en active Pending
- 2018-10-30 HU HUE18873778A patent/HUE067356T2/hu unknown
- 2018-10-30 EP EP18873778.7A patent/EP3704108B1/en active Active
- 2018-10-31 US US16/176,940 patent/US10758518B2/en active Active
-
2020
- 2020-04-21 PH PH12020550457A patent/PH12020550457A1/en unknown
- 2020-07-13 MX MX2023010882A patent/MX2023010882A/es unknown
- 2020-07-21 US US16/934,724 patent/US20200345704A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/566,371 patent/US20220370422A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034551A patent/JP7476380B2/ja active Active
- 2023-08-30 AU AU2023222890A patent/AU2023222890B2/en active Active
-
2024
- 2024-04-17 JP JP2024066487A patent/JP2024096919A/ja not_active Withdrawn
-
2025
- 2025-07-10 AU AU2025205341A patent/AU2025205341A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274248A (en) | Compounds and preparations for the treatment of hematological disorders | |
| HUE062648T2 (hu) | Vegyületek és készítmények hematológiai rendellenességek kezelésére | |
| IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
| IL275506A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| IL275562A (en) | Preparations and methods for the treatment of central nervous system disorders | |
| ZA201803530B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| ZA201801881B (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SMT202100113T1 (it) | Composizioni e metodi per trattare disturbi del snc | |
| PT3206493T (pt) | Composições e métodos para tratamento de transtornos do snc | |
| PT3224269T (pt) | Composições e métodos para tratamento de distúrbios do snc | |
| EP3280420A4 (en) | Compositions and methods for treating cns disorders | |
| IL269637A (en) | Preparations and methods for the treatment of synovial diseases | |
| IL272061A (en) | Preparations for the treatment of stress-related disorders | |
| ZA201800831B (en) | Compositions and methods for treating and preventing neurodegenerative disorders | |
| HUE059400T2 (hu) | Az amiloidózis kezelésére szolgáló készítmények | |
| EP3262065A4 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
| IL268715A (en) | Preparations for the treatment of acne | |
| HK40040286A (en) | Compositions and methods for treating cns disorders | |
| HK40006088A (en) | Compositions for treating acid-base disorders |